These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21861306)

  • 1. [Combination therapy with macrolides for pneumonia].
    Mikamo H; Yamagishi Y
    Jpn J Antibiot; 2011 Jun; 64(3):117-24. PubMed ID: 21861306
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.
    Emmet O'Brien M; Restrepo MI; Martin-Loeches I
    Respir Investig; 2015 Sep; 53(5):201-9. PubMed ID: 26344609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrolide combination antibiotic therapy should be prudently considered in complicated CAP cases and in regions with low macrolide susceptibility.
    Shih HI; Hsu HC; Chi CH; Ko WC
    Intensive Care Med; 2010 Oct; 36(10):1788. PubMed ID: 20631990
    [No Abstract]   [Full Text] [Related]  

  • 4. [Preventive measures for drug resistant bacteria by guidelines].
    Tomono K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():531-3. PubMed ID: 17455675
    [No Abstract]   [Full Text] [Related]  

  • 5. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Empirical antibacterial therapy of community acquired pneumonia in outpatients].
    Yakovlev SV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):23-8. PubMed ID: 9412399
    [No Abstract]   [Full Text] [Related]  

  • 7. Macrolides and community-acquired pneumonia: is quorum sensing the key?
    Wise MP; Williams DW; Lewis MA; Frost PJ
    Crit Care; 2010; 14(4):181. PubMed ID: 20663182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
    Esposito S; Fiore M
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078
    [No Abstract]   [Full Text] [Related]  

  • 9. Timely antibiotic therapy for community-acquired pneumonia.
    Mansel JK
    J Miss State Med Assoc; 2004 May; 45(5):159. PubMed ID: 15162706
    [No Abstract]   [Full Text] [Related]  

  • 10. Drugs of choice for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2007 Jul; 49(1266):62-4. PubMed ID: 17652999
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review.
    Kovaleva A; Remmelts HH; Rijkers GT; Hoepelman AI; Biesma DH; Oosterheert JJ
    J Antimicrob Chemother; 2012 Mar; 67(3):530-40. PubMed ID: 22190609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN; Yu VL
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Japanese Respiratory Society guidelines for management of community-acquired pneumonia in adults].
    Matsushima T;
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():677-81. PubMed ID: 12722300
    [No Abstract]   [Full Text] [Related]  

  • 14. [Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association].
    Strålin K; Goscinski G; Hedlund J; Lidman C; Spindler C; Ortqvist A; Holmberg H
    Lakartidningen; 2008 Sep 17-23; 105(38):2582-7. PubMed ID: 18846863
    [No Abstract]   [Full Text] [Related]  

  • 15. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
    Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Empiric treatment of community-acquired pneumonia].
    Fálco Ferrer V; Almirante Gragera B; Pahissa Berga A
    Rev Clin Esp; 2004 Feb; 204(2):103-5. PubMed ID: 15023311
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia].
    Iutanova NS
    Antibiot Khimioter; 2004; 49(3):17-21. PubMed ID: 15344392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
    Teh B; Grayson ML; Johnson PD; Charles PG
    Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
    Laterre PF
    Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia.
    Ferrer M; Menendez R; Amaro R; Torres A
    Clin Chest Med; 2011 Sep; 32(3):491-505. PubMed ID: 21867818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.